PURPOSE: To test the hypotheses that (1) the increased risk of stroke conferred by childhood cranial radiation therapy (CRT) persists into adulthood; and (2) atherosclerotic risk factors further increase the stroke risk in cancer survivors. METHODS AND MATERIALS: The Childhood Cancer Survivor Study is a multi-institutional retrospective cohort study of 14,358 5-year survivors of childhood cancer and 4023 randomly selected sibling controls with longitudinal follow-up. Age-adjusted incidence rates of self-reported late-occurring (≥5 years after diagnosis) first stroke were calculated. Multivariable Cox proportional hazards models were used to identify independent stroke predictors. RESULTS: During a mean follow-up of 23.3 years, 292 survivors reported a late-occurring stroke. The age-adjusted stroke rate per 100,000 person-years was 77 (95% confidence interval [CI] 62-96), compared with 9.3 (95% CI 4-23) for siblings. Treatment with CRT increased stroke risk in a dose-dependent manner: hazard ratio 5.9 (95% CI 3.5-9.9) for 30-49 Gy CRT and 11.0 (7.4-17.0) for 50+ Gy CRT. The cumulative stroke incidence in survivors treated with 50+ Gy CRT was 1.1% (95% CI 0.4-1.8%) at 10 years after diagnosis and 12% (95% CI 8.9-15.0%) at 30 years. Hypertension increased stroke hazard by 4-fold (95% CI 2.8-5.5) and in black survivors by 16-fold (95% CI 6.9-36.6). CONCLUSION: Young adult pediatric cancer survivors have an increased stroke risk that is associated with CRT in a dose-dependent manner. Atherosclerotic risk factors enhanced this risk and should be treated aggressively.
PURPOSE: To test the hypotheses that (1) the increased risk of stroke conferred by childhood cranial radiation therapy (CRT) persists into adulthood; and (2) atherosclerotic risk factors further increase the stroke risk in cancer survivors. METHODS AND MATERIALS: The Childhood Cancer Survivor Study is a multi-institutional retrospective cohort study of 14,358 5-year survivors of childhood cancer and 4023 randomly selected sibling controls with longitudinal follow-up. Age-adjusted incidence rates of self-reported late-occurring (≥5 years after diagnosis) first stroke were calculated. Multivariable Cox proportional hazards models were used to identify independent stroke predictors. RESULTS: During a mean follow-up of 23.3 years, 292 survivors reported a late-occurring stroke. The age-adjusted stroke rate per 100,000 person-years was 77 (95% confidence interval [CI] 62-96), compared with 9.3 (95% CI 4-23) for siblings. Treatment with CRT increased stroke risk in a dose-dependent manner: hazard ratio 5.9 (95% CI 3.5-9.9) for 30-49 Gy CRT and 11.0 (7.4-17.0) for 50+ Gy CRT. The cumulative stroke incidence in survivors treated with 50+ Gy CRT was 1.1% (95% CI 0.4-1.8%) at 10 years after diagnosis and 12% (95% CI 8.9-15.0%) at 30 years. Hypertension increased stroke hazard by 4-fold (95% CI 2.8-5.5) and in black survivors by 16-fold (95% CI 6.9-36.6). CONCLUSION: Young adult pediatric cancer survivors have an increased stroke risk that is associated with CRT in a dose-dependent manner. Atherosclerotic risk factors enhanced this risk and should be treated aggressively.
Authors: Ali H Mokdad; Earl S Ford; Barbara A Bowman; William H Dietz; Frank Vinicor; Virginia S Bales; James S Marks Journal: JAMA Date: 2003-01-01 Impact factor: 56.272
Authors: Lucille D A Dorresteijn; Arnoud C Kappelle; Natasja M J Scholz; Marten Munneke; José T Scholma; Alfons J M Balm; Harry Bartelink; Willem Boogerd Journal: Eur J Cancer Date: 2005-05 Impact factor: 9.162
Authors: Susanna J E Veringa; Eline van Dulmen-den Broeder; Gertjan J L Kaspers; Margreet A Veening Journal: Pediatr Blood Cancer Date: 2011-07-25 Impact factor: 3.167
Authors: Corinna Koebnick; Ning Smith; Karl Huang; Mayra P Martinez; Heather A Clancy; Lawrence H Kushi Journal: Ann Epidemiol Date: 2012-07-04 Impact factor: 3.797
Authors: Salina P Waddy; George Cotsonis; Michael J Lynn; Michael R Frankel; Seemant Chaturvedi; Janice E Williams; Marc Chimowitz Journal: Stroke Date: 2008-10-02 Impact factor: 7.914
Authors: Roger J Packer; James G Gurney; Judy A Punyko; Sarah S Donaldson; Peter D Inskip; Marilyn Stovall; Yutaka Yasui; Ann C Mertens; Charles A Sklar; H Stacy Nicholson; Lonnie K Zeltzer; Joseph P Neglia; Leslie L Robison Journal: J Clin Oncol Date: 2003-09-01 Impact factor: 50.717
Authors: Heather J Fullerton; Kayla Stratton; Sabine Mueller; Wendy W Leisenring; Greg T Armstrong; Rita E Weathers; Marilyn Stovall; Charles A Sklar; Robert E Goldsby; Les L Robison; Kevin R Krull Journal: Neurology Date: 2015-08-26 Impact factor: 9.910
Authors: M Douglas Ris; Wendy M Leisenring; Pamela Goodman; Chongzhi Di; Jennie Noll; Wendy Levy; Leslie L Robison; Gregory T Armstrong Journal: Cancer Date: 2019-06-24 Impact factor: 6.860
Authors: Lisa M Jacola; Kim Edelstein; Wei Liu; Ching-Hon Pui; Robert Hayashi; Nina S Kadan-Lottick; Deokumar Srivastava; Tara Henderson; Wendy Leisenring; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: Lancet Psychiatry Date: 2016-09-14 Impact factor: 27.083
Authors: Giselle K Perez; Anne C Kirchhoff; Christopher Recklitis; Kevin R Krull; Karen A Kuhlthau; Paul C Nathan; Julia Rabin; Gregory T Armstrong; Wendy Leisenring; Leslie L Robison; Elyse R Park Journal: J Cancer Surviv Date: 2018-04-15 Impact factor: 4.442
Authors: Kevin R Krull; Yutaka Yasui; Yadav Sapkota; Yin Ting Cheung; Wonjong Moon; Kyla Shelton; Carmen L Wilson; Zhaoming Wang; Daniel A Mulrooney; Jinghui Zhang; Gregory T Armstrong; Melissa M Hudson; Leslie L Robison Journal: Clin Cancer Res Date: 2019-08-28 Impact factor: 12.531
Authors: Ayal A Aizer; Malak Abedalthagafi; Wenya Linda Bi; Margaret C Horvath; Nils D Arvold; Ossama Al-Mefty; Eudocia Q Lee; Lakshmi Nayak; Mikael L Rinne; Andrew D Norden; David A Reardon; Patrick Y Wen; Keith L Ligon; Azra H Ligon; Rameen Beroukhim; Ian F Dunn; Sandro Santagata; Brian M Alexander Journal: Neuro Oncol Date: 2015-08-30 Impact factor: 12.300